BURNABY, BC, Feb. 19, 2014 /CNW/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation protein engineering technology (HuTARG™), today announced the extension of its research collaboration with Amgen Inc. (Thousand Oaks, CA) that allows Amgen to internalize ITS' HuTARG™ technology. Under the terms of the agreement, ITS is entitled to specific license payments and development milestones.
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation platform for the generation of fully human antibody therapeutics using its proprietary HuTARG™ technology. The HuTARG™ technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit www.innovativetargeting.com
SOURCE: Innovative Targeting Solutions Inc
For further information: